All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.
Multiple myeloma (MM) is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma (SMM), or solitary plasmacytoma (SPC). However, there is a lack of data regarding the impact of these pre-existing monoclonal gammopathies (MGs) on MM outcomes.
Gaurav Goyal from the Division of Hematology, Mayo Clinic, Rochester, MN, USA, and his team utilized their institution’s data from 1973 to 2015 to ascertain the impact of prior known MGs on MM outcomes.
Dr. Goyal and his team determined that MM patients with known pre-existing MGs had superior outcome as when compared to those without. The team identified that patients with prior SMM and SPC diagnosis were associated with improved OS as compared to prior MGUS patients. The research team identified that there is a crucial need for a large prospective screening study of MGUS with a prolonged follow-up period to arrive at appropriate monitoring recommendations.
EHA-ESMO clinical practice guidelines for the diagnosis, treatment, and follow-up of MM
The European Hematology Association (EHA) and European Society for Medical Oncology (ESMO) guidelines committees have jointly issued consensus-based...
European Myeloma Network vaccine recommendations for multiple myeloma
Patients with multiple myeloma (MM) have an increased risk of infections, due to disease-related immunosuppression coupled with the immunosuppressive effect of anti-myeloma...
Subscribe to get the best content related to multiple myeloma delivered to your inbox